PTPA and neoplasm: Using an in vivo shRNA screen for immunotherapy targets, Ppp2r2d, a regulatory subunit of PP2A, when inhibited was found to be the most potent in enhancing the cytotoxic function of tumor infiltrating lymphocytes (TILs)6.